T

he whole point of the game-changing cancer immunotherapies is to get armadas of T cells sailing into battle against tumors. But for some patients there’s a fundamental problem: Their T cells aren’t armed — or, in bio-speak, “activated,” a big reason why many patients aren’t helped by much-hyped new therapies.

If a new technique reported on Monday works in people as well as it does in lab mice, however, physicians will be able to tell almost immediately if a patient’s immune system is armed and, if it’s not, quickly switch therapies, increase dosages, or just spare patients often-serious side effects.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.